Temodar — CareFirst (Caremark)
Small cell lung cancer (SCLC)
Initial criteria
- Authorization may be granted for treatment of SCLC as single agent subsequent therapy for relapsed or primary progressive disease.
Reauthorization criteria
- Authorization may be renewed if there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months